Ibrutinib, as a single agent, is productive in dealing with CLL, unique subtypes of lymphoma together with other B-cell malignancies Except unacceptable toxicity or disorder development is noticed. As a result of Persistent exposure of ibrutinib through cure, lymphoma cells could attain compensatory survival pathways, genetic mutations or clonal choice https://eddiek319chl2.wikiexpression.com/user